108,382 CareDx, Inc. $CDNA Shares Sold by Royce & Associates LP

Royce & Associates LP trimmed its holdings in shares of CareDx, Inc. (NASDAQ:CDNA) by 18.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 467,589 shares of the company’s stock after selling 108,382 shares during the quarter. Royce & Associates LP’s holdings in CareDx were worth $30,393,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Virtus Advisers LLC increased its holdings in CareDx by 5.8% during the third quarter. Virtus Advisers LLC now owns 44,475 shares of the company’s stock valued at $2,891,000 after buying an additional 2,429 shares during the last quarter. Lisanti Capital Growth LLC purchased a new position in shares of CareDx during the 3rd quarter worth $8,463,000. Allspring Global Investments Holdings LLC boosted its stake in shares of CareDx by 4.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 23,000 shares of the company’s stock worth $1,523,000 after acquiring an additional 961 shares during the last quarter. Ethic Inc. purchased a new position in shares of CareDx during the 3rd quarter worth $379,000. Finally, Alps Advisors Inc. purchased a new position in shares of CareDx during the 3rd quarter worth $720,000.

CareDx Trading Down 2.4%

CDNA traded down $1.93 on Friday, hitting $77.88. 716,354 shares of the company’s stock traded hands, compared to its average volume of 1,373,271. The company’s 50 day simple moving average is $66.34 and its 200-day simple moving average is $36.70. The firm has a market cap of $4.09 billion, a price-to-earnings ratio of 32.59 and a beta of 2.51. CareDx, Inc. has a one year low of $15.15 and a one year high of $90.87.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Thursday, October 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.45. CareDx had a return on equity of 9.74% and a net margin of 25.86%. The company had revenue of $139.36 million for the quarter, compared to analysts’ expectations of $121.96 million. During the same period in the previous year, the firm earned $0.03 EPS. The firm’s revenue was up 39.3% compared to the same quarter last year. As a group, equities analysts anticipate that CareDx, Inc. will post 1.00 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings raised shares of CareDx from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Wall Street Zen cut CareDx from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 31st. Zacks Research raised CareDx from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 5th. BTIG Research lifted their target price on CareDx from $81.00 to $92.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Finally, Craig Hallum raised CareDx from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, CareDx currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.33.

Insider Activity

In other news, CFO Keith Kennedy sold 61,961 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $77.82, for a total value of $4,821,805.02. Following the transaction, the chief financial officer owned 199,147 shares of the company’s stock, valued at approximately $15,497,619.54. The trade was a 23.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.40% of the stock is currently owned by insiders.

CareDx Company Profile

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.